Harmony Bio earnings beat by $0.40, revenue topped estimates

Oil prices turn lower as Bessent says U.S. may have Iran deal "today or tomorrow"

Investing.com - Harmony Bio (NASDAQ: HRMY) reported second quarter EPS of $1.28, $0.40 better than the analyst estimate of $0.88. Revenue for the quarter came in at $261.28M versus the consensus estimate of $242.14M.

Harmony Bio’s stock price closed at $35.60. It is up 14.88% in the last 3 months and up 8.19% in the last 12 months.

Harmony Bio saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Harmony Bio’s stock price’s past reactions to earnings here.

According to InvestingPro, Harmony Bio’s Financial Health score is "great performance".

Check out Harmony Bio’s recent earnings performance, and Harmony Bio’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Is HRMY undervalued—or a trap?

Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what HRMY is really worth.
Get instant clarity on HRMY—plus thousands of other stocks—before the opportunity disappears.